Grifols SA Ordinary Shares - Class A GRF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat
-
GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339
-
Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients
-
Troubled Spanish pharma company Grifols says it may go private for $6 billion
-
Trending: Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker
-
Grifols Faces Delisting Bid From Founding Family and Brookfield
-
Grifols shares rebound after KPMG greenlights accounts in wake of short-seller's report
-
Grifols' shares plunge further on short-seller's new report
Trading Information
- Previous Close Price
- €10.13
- Day Range
- €10.12–10.23
- 52-Week Range
- €6.36–15.92
- Bid/Ask
- — / —
- Market Cap
- €6.95 Bil
- Volume/Avg
- 1.5 Mil / 2.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- 26.67
- Price/Sales
- 1.04
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 23,737
- Website
- https://www.grifols.com
Competitors
Valuation
|
Metric
|
GRF
|
PFE
|
CSL
|
|---|---|---|---|
Price/Earnings (Normalized) | 26.67 | 20.96 | 30.03 |
Price/Book Value | 1.24 | 1.85 | 5.38 |
Price/Sales | 1.04 | 2.90 | 6.25 |
Price/Cash Flow | 10.91 | 21.18 | 33.21 |
Price/Earnings
GRF
PFE
CSL
Financial Strength
|
Metric
|
GRF
|
PFE
|
CSL
|
|---|---|---|---|
Quick Ratio | 0.77 | 0.51 | 0.87 |
Current Ratio | 1.68 | 0.86 | 2.18 |
Interest Coverage | 1.39 | −0.88 | 8.01 |
Quick Ratio
GRF
PFE
CSL
Profitability
|
Metric
|
GRF
|
PFE
|
CSL
|
|---|---|---|---|
Return on Assets (Normalized) | 1.41% | 3.50% | 7.82% |
Return on Equity (Normalized) | 5.27% | 8.28% | 17.33% |
Return on Invested Capital (Normalized) | 3.44% | 5.39% | 10.52% |
Return on Assets
GRF
PFE
CSL
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Rnnkxgvrgz | Ttrny | $798.8 Bil | |||
| Johnson & Johnson
JNJ
| Xqjfxdff | Zch | $385.9 Bil | |||
| AbbVie Inc
ABBV
| Pwvmtjxlt | Xwfm | $343.2 Bil | |||
| Merck & Co Inc
MRK
| Zplgqhxd | Rnsnl | $278.2 Bil | |||
| Roche Holding AG ADR
RHHBY
| Vwcbblbmv | Lgprq | $244.4 Bil | |||
| AstraZeneca PLC ADR
AZN
| Ckqrjycv | Jnsr | $238.9 Bil | |||
| Novartis AG ADR
NVS
| Pgjzgssfl | Znc | $232.2 Bil | |||
| Amgen Inc
AMGN
| Xtfhswjgf | Bqkv | $171.8 Bil | |||
| Pfizer Inc
PFE
| Szfnxntht | Mrj | $162.0 Bil | |||
| Sanofi SA ADR
SNY
| Qjrnzgwd | Wmtk | $140.7 Bil |
United States